SecBot SecBot
6-K ·Filed Mar 27, 2026

PHAR

Pharming Group N.V.
BULLISH
Impact 8/10
Horizonweeks Processed7mo ago SEC0001828316-26-000012
Notable filing: 6-K
Actionable Insight ▲ Bullish

Monitor for the final European Commission decision expected in Q2 2026, which could trigger positive price movement. The approval would open a new market for Joenja as the first treatment for APDS in Europe.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$16.31
T+0 close · Mar 27, 2026 · via day close
Latest settled
−20.23%
T+60 · $13.01
Vs SPY
−36.30%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 27 $16.31entry
  2. T+1 · 8mo ago −1.84%α −1.48% · $16.01
  3. T+5 · 8mo ago +1.16%α −2.70% · $16.50
  4. T+20 · 7mo ago +3.74%α −9.00% · $16.92
  5. T+60 · 5mo ago −20.23%α −36.30% · $13.01
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pharming Group received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorization for Joenja (leniolisib) for the treatment of activated phosphoinositide 3-kinase delta (PI3K) syndrome (APDS) in adult and pediatric patients 12 years and older. If approved by the European Commission, Joenja would become the first approved treatment for APDS in the European Union.

Key Facts

  • CHMP adopted a positive opinion recommending marketing authorization for Joenja (leniolisib) for APDS treatment
  • Final European Commission decision expected in Q2 2026
  • If approved, Joenja would be the first treatment for APDS in the EU
  • Approval would be valid in all 27 EU member states plus Norway, Iceland, and Liechtenstein
  • Joenja is already approved in the US, UK, Japan, Australia, and Israel
  • Decision based on Phase III clinical trial data showing statistically significant impact

Financial Impact

Potential for significant revenue growth if approved in EU market

revenuemarket sharevaluation

Risk Factors

  • European Commission could reject the recommendation despite positive CHMP opinion
  • Commercial uptake may be limited due to APDS being a rare disease affecting 1-2 people per million

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001828316-26-000012
Document: 0001828316-26-000012-index-headers.html0001828316-26-000012
Document: 0001828316-26-000012-index.html0001828316-26-000012
Document: 0001828316-26-000012.txt0001828316-26-000012

Track record

18 reports on PHAR

Performance horizon

8 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +39.00% at T+20 after the Oct 14, 2026 report. 10 of 14 went positive at some point.

Filters
  1. Nov 6, 202610d ago 6-K Bullish 5/10 Entry $12.29 to $12.60 Now $12.59 +2.44% ▲ +2.52% −0.07% vs SPY
  2. Nov 6, 202611d ago Press Release Bullish 6/10 Entry $12.29 to $12.60 Now $12.59 +2.44% ▲ +2.52% −0.07% vs SPY
  3. Oct 27, 202620d ago 6-K Bullish 6/10 No price data
  4. Oct 27, 202621d ago Press Release Bullish 6/10 Entry $11.87 to $12.93 Now $12.59 +6.07% ▲ +8.93% +10.92% vs SPY
  5. Oct 22, 202625d ago 6-K Bullish 6/10 Entry $10.67 to $11.86 Now $12.59 +17.99% ▲ +11.15% +10.45% vs SPY
  6. Oct 14, 20264w ago 6-K Bullish 6/10 Entry $9.64 to $9.65 Now $12.59 +30.60% ▲ +0.10% −0.35% vs SPY
  7. Sep 29, 20266w ago 6-K Bearish 5/10 Entry $10.01 to $9.68 Now $12.59 −25.77% ▲ +3.30% +5.25% vs SPY
  8. Sep 29, 20267w ago Press Release Bearish 6/10 Entry $10.01 to $9.68 Now $12.59 −25.77% ▲ +3.30% +5.25% vs SPY
  9. Sep 25, 20267w ago 6-K Bullish 6/10 Entry $10.46 to $9.75 Now $12.59 +20.36% ▼ −6.79% −6.57% vs SPY
  10. Sep 25, 20267w ago Press Release Bullish 5/10 Entry $10.46 to $9.75 Now $12.59 +20.36% ▼ −6.79% −6.57% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 27, 2026